198 related articles for article (PubMed ID: 25216229)
1. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.
Tan HL; Haffner MC; Esopi DM; Vaghasia AM; Giannico GA; Ross HM; Ghosh S; Hicks JL; Zheng Q; Sangoi AR; Yegnasubramanian S; Osunkoya AO; De Marzo AM; Epstein JI; Lotan TL
Mod Pathol; 2015 Mar; 28(3):446-56. PubMed ID: 25216229
[TBL] [Abstract][Full Text] [Related]
2. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
3. TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
Galoczova M; Nenutil R; Pokorna Z; Vojtesek B; Coates PJ
Virchows Arch; 2021 Apr; 478(4):627-636. PubMed ID: 33037932
[TBL] [Abstract][Full Text] [Related]
4. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
Fonseca-Alves CE; Kobayashi PE; Rivera Calderón LG; Felisbino SL; Rinaldi JC; Drigo SA; Rogatto SR; Laufer-Amorim R
PLoS One; 2018; 13(6):e0199173. PubMed ID: 29894516
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
7. A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis.
Baydar DE; Kulac I; Gurel B; De Marzo A
Int J Surg Pathol; 2011 Feb; 19(1):131-6. PubMed ID: 20719821
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
[TBL] [Abstract][Full Text] [Related]
9. Cell differentiation lineage in the prostate.
Wang Y; Hayward S; Cao M; Thayer K; Cunha G
Differentiation; 2001 Oct; 68(4-5):270-9. PubMed ID: 11776479
[TBL] [Abstract][Full Text] [Related]
10. Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
Wu M; Ingram L; Tolosa EJ; Vera RE; Li Q; Kim S; Ma Y; Spyropoulos DD; Beharry Z; Huang J; Fernandez-Zapico ME; Cai H
J Biol Chem; 2016 Dec; 291(49):25749-25760. PubMed ID: 27760825
[TBL] [Abstract][Full Text] [Related]
11. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
12. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
14. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.
Vidal I; Zheng Q; Hicks JL; Chen J; Platz EA; Trock BJ; Kulac I; Baena-Del Valle JA; Sfanos KS; Ernst S; Jones T; Maynard JP; Glavaris SA; Nelson WG; Yegnasubramanian S; De Marzo AM
PLoS One; 2021; 16(6):e0241934. PubMed ID: 34191807
[TBL] [Abstract][Full Text] [Related]
15. Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells.
He Y; Hooker E; Yu EJ; Cunha GR; Liao L; Xu J; Earl A; Wu H; Gonzalgo ML; Sun Z
Oncogene; 2019 Mar; 38(13):2337-2350. PubMed ID: 30510232
[TBL] [Abstract][Full Text] [Related]
16. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
17. p63 is a prostate basal cell marker and is required for prostate development.
Signoretti S; Waltregny D; Dilks J; Isaac B; Lin D; Garraway L; Yang A; Montironi R; McKeon F; Loda M
Am J Pathol; 2000 Dec; 157(6):1769-75. PubMed ID: 11106548
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics.
Wu A; Kunju LP
Arch Pathol Lab Med; 2013 Sep; 137(9):1179-84. PubMed ID: 23991727
[TBL] [Abstract][Full Text] [Related]
19. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
